Announced Tue, 11 Aug · 18:15 IST
Board approves Q1 FY27 results, appoints new statutory auditor
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.7%1-day move
₹39.25
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-5.7-3.3-4.4-3.2-3.2-3.2-3.1-5.8——
Up moveDown movePending
AI summary
Sandu Pharmaceuticals board approved Q1 FY27 (June 2026) standalone results with revenue from operations at Rs 1638.88 lakhs and profit after tax of Rs 2.83 lakhs (EPS Rs 0.37). Board appointed M/s Dave & Dave Chartered Accountants as statutory auditor for first term of 5 years (FY2026-27 to FY2030-31), replacing Dileep & Prithvi whose term ended. 41st AGM set for September 11, 2026 via video conferencing. Record date for dividend eligibility is September 4, 2026.
Likely market impact
Routine auditor rotation after term completion; modest Q1 profit; AGM and dividend record date announced for shareholder action.